Clinical Trials

BreastGastrointestinalGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck

NCT07216105 2025-12-17

FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

Phase 1 Recruiting

113 enrolled

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT04722523 2025-09-23

A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer

Phase 1 Recruiting

40 enrolled

Phase 1 Active not recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT03498378 2025-04-03

Avelumab, Cetuximab, and Palbociclib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

24 enrolled

Squamous Cell Carcinoma of Head and Neck, Neoplasms

NCT04091867 2025-02-24

sEphB4-HSA With RT+Chemo or Cetux in Patients With Intermediate to High Risk LAHNSCC

3 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT01935921 2023-06-15

Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck Cancer

19 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT02764593 2022-11-29

Safety Testing of Adding Nivolumab to Chemotherapy in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Cancer

40 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT02438995 2021-11-03

Super-Selective Intraarterial Infusion of Cetuximab (Erbitux) With or Without Radiation Therapy for the Treatment of Unresectable Recurrent Squamous Cell Carcinoma of the Head and Neck

11 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

NCT02938273 2019-12-11

Bioimmunoradiotherapy (Cetuximab/RT/Avelumab)

10 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT02124850 2019-10-25

A Phase Ib Study of Neoadjuvant of Cetuximab Plus Motolimod and Cetuximab Plus Motolimod Plus Nivolumab

18 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT01758731 2019-09-23

Study of Olaparib With Radiation Therapy and Cetuximab in Advanced Head and Neck Cancer With Heavy Smoking History

17 enrolled 8 charts

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Smoking

NCT02277197 2019-04-18

Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

14 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT01716416 2019-04-16

HNSCC

32 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT02205398 2019-01-22

Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy

GastrointestinalHead & Neck

13 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Laryngeal Diseases, Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT00882583 2019-01-09

Dasatinib

22 enrolled 8 charts

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT02350712 2018-09-11

Patritumab With Cetuximab and a Platinum Containing Therapy for Patients With Head and Neck Cancer

15 enrolled

Squamous Cell Carcinoma of Head and Neck, Recurrence

NCT00397384 2015-09-30

Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer